Apalutamide Clinical Trials
21 recruitingDrug
Phase 29Phase 37Phase 13Not Applicable2
Showing 1–20 of 21 trials
Recruiting
Phase 3
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Metastatic Castration-resistant Prostate Cancer
AstraZeneca670 enrolled90 locationsNCT07611110
Recruiting
Phase 3
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
Prostate CancerAndrogen Axis SuppressionProstatectomy
M.D. Anderson Cancer Center120 enrolled5 locationsNCT06274047
Recruiting
Phase 3
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Metastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8Biochemically Recurrent Prostate Carcinoma+1 more
ECOG-ACRIN Cancer Research Group804 enrolled342 locationsNCT04423211
Recruiting
Phase 2
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
Prostate CarcinomaStage III Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8+4 more
M.D. Anderson Cancer Center200 enrolled1 locationNCT04947254
Recruiting
Phase 3
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Stage IVB Prostate Cancer AJCC v8Metastatic Prostate AdenocarcinomaCastration-Sensitive Prostate Carcinoma
Alliance for Clinical Trials in Oncology1,260 enrolled186 locationsNCT06931340
Recruiting
Phase 1
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Metastatic Hormone Sensitive Prostate CancerMetastatic Castration-resistant Prostate Neoplasms
Janssen Research & Development, LLC300 enrolled15 locationsNCT05818683
Recruiting
Phase 3
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
Stage III Prostate Cancer AJCC v8Prostate AdenocarcinomaStage I Prostate Cancer AJCC v8+2 more
NRG Oncology586 enrolled347 locationsNCT04134260
Recruiting
Phase 1
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Prostatic Neoplasms
Janssen Research & Development, LLC355 enrolled13 locationsNCT06095089
Recruiting
Phase 2
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
Biochemically Recurrent Prostate CarcinomaRecurrent Castration-Sensitive Prostate CarcinomaRecurrent Prostate Cancer+1 more
Mayo Clinic532 enrolled3 locationsNCT06378866
Recruiting
Phase 1Phase 2
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Institute of Cancer Research, United Kingdom78 enrolled4 locationsNCT07002320
Recruiting
Phase 3
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Prostate Cancer (Adenocarcinoma)
Canadian Cancer Trials Group830 enrolled340 locationsNCT06592924
Recruiting
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
Prostatic NeoplasmsMetastatic Hormone Sensitive Prostate Cancer
Bayer1,400 enrolled1 locationNCT07406282
Recruiting
Phase 2
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
Prostate CancerMetastatic Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute26 enrolled2 locationsNCT05751941
Recruiting
Phase 2
Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
Castration-resistant Prostate Cancer
Edwin Posadas, MD100 enrolled3 locationsNCT05534646
Recruiting
Phase 2
Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial
Prostate AdenocarcinomaStage II Prostate Cancer AJCC v8Stage IIIA Prostate Cancer AJCC v8+1 more
Jonsson Comprehensive Cancer Center95 enrolled1 locationNCT06067269
Recruiting
Phase 3
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
Metastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Karolinska Institutet750 enrolled32 locationsNCT03903835
Recruiting
Phase 2
Surgical Treatment With or Without Apalutamide in Subjects With High Risk Prostate Cancer Who Are Candidates for Radical Prostatectomy and Staged as Oligometastatic With PSMA-PET
High-risk Prostate Cancer
Marco Oderda94 enrolled1 locationNCT06758882
Recruiting
Phase 2
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Advanced CancerSolid TumorHaematological Malignancy
Helsinki University Central Hospital250 enrolled5 locationsNCT05159245
Recruiting
Not Applicable
Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone Metastases
Prostate Cancer With ≤10 Bone Metastases
Zhujiang Hospital30 enrolled1 locationNCT05740488
Recruiting
Not Applicable
An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate Cancer
High-Risk and Oligometastatic Prostate Cancer
Zhujiang Hospital50 enrolled1 locationNCT04997252